Promoting granulation

Promoting granulation is a complex biological process and therapeutic objective within the proliferative phase of wound healing rather than a specific target molecule or receptor. It involves the formation of granulation tissue, a temporary matrix consisting of new connective tissue and microscopic blood vessels (angiogenesis) that grows from the base of a wound to fill the defect. This process is orchestrated by various cell types, including fibroblasts, endothelial cells, and macrophages, which respond to a cocktail of endogenous growth factors such as Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), and Transforming Growth Factor-beta (TGF-β). In a clinical context, promoting granulation is essential for the closure of chronic, non-healing wounds such as diabetic foot ulcers and pressure sores. Therapeutic interventions like becaplermin (recombinant human PDGF-BB) or trafermin (recombinant human basic fibroblast growth factor) are used to topically stimulate these pathways and accelerate tissue repair. While promoting granulation is beneficial for healing, dysregulation can lead to pathological outcomes such as excessive fibrosis (scarring) or, in the case of over-stimulation by certain growth factors, a potential increase in the risk of malignancy.

Other names

Granulation tissue formationWound granulationPromotion of wound healingGranulation tissue regeneration

Drugs promoting granulation typically act as exogenous growth factors that bind to specific tyrosine kinase receptors (e.g., PDGFR, FGFR, EGFR) to stimulate the migration and proliferation of fibroblasts and vascular endothelial cells. This induces the synthesis of extracellular matrix components like collagen and fibronectin, while simultaneously promoting angiogenesis through the upregulation of VEGF and other pro-angiogenic factors to supply the developing tissue with oxygen and nutrients.